340B Drug Pricing Program
The AHA is pleased that Johnson & Johnson has decided to cease implementation of its 340B rebate proposal, which would have harmed patients and 340B providers. We are especially appreciative of HRSA’s efforts to convince J&J to put an end to this unlawful proposal and those members of…
The Health Resources and Services Administration Sept. 27 sent a final warning letter to Johnson & Johnson urging the company to inform the agency by Monday, Sept. 30 that it would halt its proposed 340B rebate model scheduled to go into effect next month.
The Health Resources and Services Administration today sent a final warning letter to Johnson & Johnson urging the company to inform the agency by Monday, Sept. 30 that it would halt its proposed 340B rebate model scheduled to go into effect next month.
The deadline has been extended for representatives to sign onto a letter that urges the Department of Health and Human Services to take action to stop Johnson & Johnson’s plan “to upend more than 30 years of federal law by delaying access to 340B Drug Pricing Program (340B) discounts on…
University of Louisville (UofL) Health is a fully integrated regional academic health system with nine hospitals, a cancer center, an eye institute and nearly 200 clinics serving communities across Kentucky and Southern Indiana.
Urge your representatives to sign letter to HHS asking it to take action to protect providers from ‘devastating’ J&J 340B proposal; deadline is Sept. 20.
“As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their complaints ring hollow when it is clear that their own actions are driving growth in the program,” says an op-ed in Medical Economics authored by Bharath Krishnamurthy, AHA…
The Health Resources and Services Administration Sept. 17 told Johnson & Johnson that the company’s publicly announced plans to implement a 340B rebate model “violates J&J’s obligations under the 340B statute, and HRSA expects J&J to cease implementation of it.”
The Health Resources and Services Administration today told Johnson & Johnson that the company’s publicly announced plans to implement a 340B rebate model “violates J&J’s obligations under the 340B statute, and HRSA expects J&J to cease implementation of it.”
Reps. Abigail Spanberger (D-Va.), Dusty Johnson (R-S.D.), Doris Matsui (D-Calif.), Debbie Dingell (D-Mich.), Tracey Mann (R-Kan.) and Rob Wittman (R-Va.) are asking representatives to sign onto a letter to the Department of Health and Human Services urging it to take action to stop Johnson &…